Progestogens in Menopausal Hormone Therapy
January 2015
in “
Przeglad Menopauzalny
”
TLDR Progestogens are essential in menopausal hormone therapy to prevent uterine cancer and must be chosen carefully based on individual needs.
The document from 2015 reviews the role of progestogens in menopausal hormone therapy (MHT), emphasizing their critical role in preventing endometrial hyperplasia and cancer in women with an intact uterus. It discusses the selection of progestogens based on their action mechanisms, side effects, and the need to consider aging-related changes in drug pharmacokinetics. Various progestogens, such as dienogest, drospirenone, dydrogesterone, levonorgestrel, norethisterone, cyproterone acetate, and medroxyprogesterone acetate, are examined for their specific uses in MHT and contraception, and their effects on lipid profiles, coagulation, carbohydrate metabolism, and bleeding patterns. The document also explores the impact of progestogens on breast cancer risk and cardiovascular health, indicating that understanding their differences is crucial for tailoring MHT to individual patient needs.
